drugset / Trial / NCT03466242

IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures

NCT03466242

Phase 0 Withdrawn Phoenix Children's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the sedative, and analgesic effects of intranasal (IN) Dexmedetomidine (DEX) in children presenting to a Pediatric Emergency Department (PED) who undergo conscious sedation for reduction of closed distal forearm fractures when compared to those receiving intravenous (IV) Ketamine. The secondary objective is to compare each sedation technique for safety and procedural outcomes.

Timeline

Start
2017-01-01
Primary completion
2020-01-01
Completion
2020-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ug/kg Intranasal
Subject Dexmedetomidine Other / unclassified 2 ug/kg Intranasal
Comparator Ketamine Small molecule 1 mg/kg Intravenous

Indications

No indication recorded.